Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 17-(cyclopropylmethyl)-6,7-didehydro-4,5alpha-epoxy-3,6,14-trihydroxy-n-(2-(3-phenyl- 1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide
2. Naldemedine
3. S-297995
4. Symproic
1. Symproic
2. Naldemedine Tosilate
3. Naldemedine Tosylate [usan]
4. Naldemedine (tosylate)
5. V1n8f1rvvo
6. 1345728-04-2
7. Unii-v1n8f1rvvo
8. Symproic (tn)
9. Chembl3039508
10. Schembl20720003
11. Dtxsid10158809
12. Naldemedine Tosylate [mi]
13. Naldemedine Tosylate (jan/usan)
14. Naldemedine Tosilate [jan]
15. Hy-19627a
16. Naldemedine Tosilate [who-dd]
17. Naldemedine Tosylate [orange Book]
18. Cs-0030916
19. D10478
20. Q27291424
21. 17-(cyclopropylmethyl)-6,7-didehydro-4,5a-epoxy-3,6,14-trihydroxy-n-(2-(3-phenyl-1,2,4-oxadiazol-5-yl)propan-2-yl)morphinan-7-carboxamide 4-methylbenzenesulfonic Acid
22. Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-n-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5.alpha.)-, 4-methylbenzenesulfonate (1:1)
23. Morphinan-7-carboxamide, 17-(cyclopropylmethyl)-6,7-didehydro-4,5-epoxy-3,6,14-trihydroxy-n-(1-methyl-1-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl)-,(5alpha)-, 4-methylbenzenesulfonate (1:1)
Molecular Weight | 742.8 g/mol |
---|---|
Molecular Formula | C39H42N4O9S |
Hydrogen Bond Donor Count | 5 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 7 |
Exact Mass | 742.26725010 g/mol |
Monoisotopic Mass | 742.26725010 g/mol |
Topological Polar Surface Area | 204 Ų |
Heavy Atom Count | 53 |
Formal Charge | 0 |
Complexity | 1340 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 1 | |
---|---|
Drug Name | SYMPROIC |
Active Ingredient | NALDEMEDINE TOSYLATE |
Company | SHIONOGI INC (Application Number: N208854. Patents: 9108975, RE46365, RE46375) |
Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.
Treatment of opioid-induced constipation (OIC)
A06AH05
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Naldemedine Tosylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naldemedine Tosylate, including repackagers and relabelers. The FDA regulates Naldemedine Tosylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naldemedine Tosylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Naldemedine Tosylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Naldemedine Tosylate supplier is an individual or a company that provides Naldemedine Tosylate active pharmaceutical ingredient (API) or Naldemedine Tosylate finished formulations upon request. The Naldemedine Tosylate suppliers may include Naldemedine Tosylate API manufacturers, exporters, distributors and traders.
click here to find a list of Naldemedine Tosylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Naldemedine Tosylate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Naldemedine Tosylate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Naldemedine Tosylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Naldemedine Tosylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Naldemedine Tosylate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Naldemedine Tosylate suppliers with NDC on PharmaCompass.
Naldemedine Tosylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Naldemedine Tosylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naldemedine Tosylate GMP manufacturer or Naldemedine Tosylate GMP API supplier for your needs.
A Naldemedine Tosylate CoA (Certificate of Analysis) is a formal document that attests to Naldemedine Tosylate's compliance with Naldemedine Tosylate specifications and serves as a tool for batch-level quality control.
Naldemedine Tosylate CoA mostly includes findings from lab analyses of a specific batch. For each Naldemedine Tosylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Naldemedine Tosylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Naldemedine Tosylate EP), Naldemedine Tosylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naldemedine Tosylate USP).
LOOKING FOR A SUPPLIER?